Our Company was incorporated as a private limited company under the Companies Act, 1956, with the name and style of `Inbiopro Solutions Private Limited' and a certificate of incorporation dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The name of our Company was then changed to `Stelis Biopharma Private Limited', pursuant to a scheme of amalgamation and a certificate of incorporation pursuant to change of name dated December 24, 2014, was issued by the Registrar of Companies, Karnataka at Bangalore. Our Company was then converted from a private limited company to a public company on July 31, 2021, and consequently renamed as `Stelis Biopharma Limited' and a fresh certificate of incorporation dated July 31, 2021, was issued by the Registrar of Companies, Karnataka at Bangalore. Subsequently, the name of our Company was changed to its present name `Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.
Major Events and Milestones: 2007 - Our Company was incorporated under the name and style of `Inbiopro Solutions Private Limited'
2014 - The name of our Company was changed to `Stelis Biopharma Private Limited'
2021 - Our Company was converted from a private limited company to a public limited company and consequently renamed as `Stelis Biopharma Limited'
2024 - The name of our Company was changed to `Onesource Specialty Pharma Limited' - Demerger, transfer and vesting of the Demerged Undertaking from Strides and Steriscience into our Company on a going concern basis pursuant to the Scheme of Arrangement
2025 -OneSource Specialty Pharma Limited and Sweden-based biotechnology firm Xbrane Biopharma AB (listed on Nasdaq under the ticker XBRANE), have announced a strategic partnership for the commercial manufacturing of Xbrane’s biosimilar portfolio for global markets. -OneSource Specialty Pharma Limited has received a "Voluntary Action Indicated" (VAI) classification from
the U.S. Food and Drug Administration (USFDA), confirming its continued compliance.
|